NasdaqCM:PDEX

Stock Analysis Report

Executive Summary

Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide.

Snowflake

Fundamentals

Outstanding track record with excellent balance sheet.

Risks

  • Pro-Dex has significant price volatility in the past 3 months.
  • Pro-Dex is covered by less than 3 analysts.

Share Price & News

How has Pro-Dex's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

10.7%

NasdaqCM:PDEX

-1.2%

US Medical Equipment

1.2%

US Market


1 Year Return

49.3%

NasdaqCM:PDEX

8.7%

US Medical Equipment

1.7%

US Market

PDEX outperformed the Medical Equipment industry which returned 8.7% over the past year.

PDEX outperformed the Market in United States of America which returned 1.7% over the past year.


Share holder returns

PDEXIndustryMarket
7 Day10.7%-1.2%1.2%
30 Day10.1%1.4%4.9%
90 Day33.3%4.8%3.7%
1 Year49.3%49.3%9.6%8.7%3.9%1.7%
3 Year196.3%196.3%70.8%65.5%47.2%37.7%
5 Year451.3%451.3%130.4%104.1%60.0%42.4%

Price Volatility Vs. Market

How volatile is Pro-Dex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Pro-Dex undervalued based on future cash flows and its price relative to the stock market?

15.54x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

Pro-Dex's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Pro-Dex's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Pro-Dex is good value based on earnings compared to the US Medical Equipment industry average.

Pro-Dex is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Pro-Dex is poor value based on expected growth next year.


Price Based on Value of Assets

Pro-Dex is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Pro-Dex expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

7.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Pro-Dex's revenue is expected to grow by 3.9% yearly, however this is not considered high growth (20% yearly).

Pro-Dex's earnings are expected to grow by 7.2% yearly, however this is not considered high growth (20% yearly).

Pro-Dex's revenue growth is positive but not above the United States of America market average.

Pro-Dex's earnings growth is positive but not above the United States of America market average.

Pro-Dex's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Pro-Dex will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Pro-Dex performed over the past 5 years?

46.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Pro-Dex has delivered over 20% year on year earnings growth in the past 5 years.

Pro-Dex's 1-year earnings growth exceeds its 5-year average (155.9% vs 46.6%)

Pro-Dex's earnings growth has exceeded the US Medical Equipment industry average in the past year (155.9% vs 28.9%).


Return on Equity

Pro-Dex has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).


Return on Assets

Pro-Dex used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Pro-Dex has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is Pro-Dex's financial position?


Financial Position Analysis

Pro-Dex is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Pro-Dex's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Pro-Dex's level of debt (26.5%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has increased over the past 5 years (0% vs 26.5% today).

Debt is well covered by operating cash flow (73.8%, greater than 20% of total debt).

Pro-Dex earns more interest than it pays, coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 4.8x debt.


Next Steps

Dividend

What is Pro-Dex's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Pro-Dex's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Pro-Dex's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Pro-Dex has not reported any payouts.

Unable to verify if Pro-Dex's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Pro-Dex has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Pro-Dex's salary, the management and board of directors tenure and is there insider trading?

6.7yrs

Average board tenure


CEO

Rick Van Kirk (58yo)

4.7yrs

Tenure

US$287,156

Compensation

Mr. Richard Lee Van Kirk, Jr., also known as Rick, has been the Chief Executive Officer and President of Pro-Dex Inc., since January 12, 2015 and has been its Chief Operating Officer since April 23, 2013.  ...


CEO Compensation Analysis

Rick's remuneration is lower than average for companies of similar size in United States of America.

Rick's compensation has been consistent with company performance over the past year, both up more than 20%.


Board Age and Tenure

6.7yrs

Average Tenure

56yo

Average Age

The tenure for the Pro-Dex board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUS$46,37514 May 19
Richard Van Kirk
EntityIndividual
Role
Chief Executive Officer
CEO, President
Shares3,500
Max PriceUS$13.25
SellUS$38,72026 Mar 19
David Hovda
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,700
Max PriceUS$14.34
SellUS$401,17114 Feb 19
AO Partners Llc
EntityCompany
Shares25,561
Max PriceUS$15.74
SellUS$33,41914 Feb 19
Alisha Charlton
EntityIndividual
Role
Chief Financial Officer
CFO & Corporate Secretary
Shares2,114
Max PriceUS$15.81
SellUS$91,61118 Dec 18
David Hovda
EntityIndividual
Role
Member of the Board of Directors
Director
Shares7,000
Max PriceUS$13.15
SellUS$75,59404 Dec 18
Farnam Street Capital, Inc.
EntityCompany
Shares5,160
Max PriceUS$14.65
SellUS$360,56103 Dec 18
Farnam Street Capital, Inc.
EntityCompany
Shares24,827
Max PriceUS$14.73
SellUS$21,43803 Dec 18
Richard Van Kirk
EntityIndividual
Role
Chief Executive Officer
CEO, President
Shares1,500
Max PriceUS$14.30
SellUS$174,70630 Nov 18
Farnam Street Capital, Inc.
EntityCompany
Shares12,091
Max PriceUS$14.74
SellUS$115,82329 Nov 18
Farnam Street Capital, Inc.
EntityCompany
Shares8,043
Max PriceUS$14.43
SellUS$140,23127 Nov 18
Farnam Street Capital, Inc.
EntityCompany
Shares9,691
Max PriceUS$14.80
SellUS$553,84127 Nov 18
AO Partners Llc
EntityCompany
Shares39,130
Max PriceUS$14.25
SellUS$371,86321 Nov 18
AO Partners Llc
EntityCompany
Shares26,116
Max PriceUS$14.25
SellUS$88,57920 Nov 18
Farnam Street Capital, Inc.
EntityCompany
Shares6,000
Max PriceUS$15.21

Ownership Breakdown


Management Team

  • Alisha Charlton (49yo)

    CFO & Corporate Secretary

    • Tenure: 4.7yrs
    • Compensation: US$193.92k
  • Rick Van Kirk (58yo)

    CEO, President

    • Tenure: 4.7yrs
    • Compensation: US$287.16k

Board Members

  • Ray Cabillot (56yo)

    Director

    • Tenure: 6.7yrs
    • Compensation: US$18.00k
  • David Hovda (56yo)

    Director

    • Tenure: 6.7yrs
    • Compensation: US$25.00k
  • Nick Swenson (50yo)

    Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$18.00k
  • Rick Van Kirk (58yo)

    CEO, President

    • Tenure: 4.7yrs
    • Compensation: US$287.16k
  • Bill Farrell (46yo)

    Director

    • Tenure: 6.7yrs
    • Compensation: US$18.00k

Company Information

Pro-Dex, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Pro-Dex, Inc.
  • Ticker: PDEX
  • Exchange: NasdaqCM
  • Founded: 1978
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$61.362m
  • Shares outstanding: 3.99m
  • Website: https://www.pro-dex.com

Number of Employees


Location

  • Pro-Dex, Inc.
  • 2361 McGaw Avenue
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PDEXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDAug 1986
PDXNDB (Deutsche Boerse AG)YesCommon StockDEEURAug 1986

Biography

Pro-Dex, Inc., together with its subsidiaries, designs, develops, and manufactures powered surgical instruments, dental instruments, and rotary air motors worldwide. It also manufactures plastic injection  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/15 00:17
End of Day Share Price2019/09/13 00:00
Earnings2019/06/30
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.